These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38709651)

  • 1. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.
    Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H
    Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia.
    Ahmad O; Omer MH; Janjua M; Alayary I; Fathala A; Alsergani H; Alamro B; Damy T; Fadel B; Mohty D
    ESC Heart Fail; 2024 Dec; 11(6):4348-4359. PubMed ID: 39219298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing hypertensive cardiomyopathy from cardiac amyloidosis in hypertensive patients with heart failure: a CMR study with histological confirmation.
    Gil KE; Truong V; Liu C; Ibrahim DY; Mikrut K; Satoskar A; Varghese J; Kahwash R; Han Y
    Int J Cardiovasc Imaging; 2024 Dec; 40(12):2559-2570. PubMed ID: 39417970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography.
    Ferkh A; Geenty P; Stefani L; Emerson P; Pham J; Byth K; Boyd AC; Richards D; Taylor MS; Kwok F; Kizana E; Thomas L
    ESC Heart Fail; 2024 Dec; 11(6):4139-4147. PubMed ID: 39129371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac biomarkers for screening and prognostication of cardiac dysfunction in critically ill patients.
    Cavefors O; Einarsson F; Holmqvist J; Bech-Hanssen O; Ricksten SE; Redfors B; Oras J
    ESC Heart Fail; 2024 Dec; 11(6):4009-4018. PubMed ID: 39087599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy.
    Fontana M; Solomon SD; Kachadourian J; Walsh L; Rocha R; Lebwohl D; Smith D; Täubel J; Gane EJ; Pilebro B; Adams D; Razvi Y; Olbertz J; Haagensen A; Zhu P; Xu Y; Leung A; Sonderfan A; Gutstein DE; Gillmore JD
    N Engl J Med; 2024 Dec; 391(23):2231-2241. PubMed ID: 39555828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter study.
    Nicol M; Kitzinger C; Baudet M; Faradji A; Pezel T; Lavergne D; Jaccard A; Vergaro G; Aimo A; Emdin M; Harel S; Royer B; Talbot A; Bousson V; Macron L; Arnulf B; Logeart D
    Amyloid; 2024 Dec; 31(4):318-325. PubMed ID: 39319571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of fourth heart sound and preserved left atrial function in wild-type transthyretin amyloidosis.
    Ochi Y; Yamasaki N; Kubo T; Baba Y; Miyagawa K; Noguchi T; Hirota T; Hamada T; Kitaoka H
    ESC Heart Fail; 2024 Dec; 11(6):4000-4008. PubMed ID: 39090841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characterization of patients with cardiac amyloidosis in a referral center of Colombia.
    Ortiz P; Polania-Sandoval CA; Gaviria-Villegas J; Gutiérrez-Villamil C; Zuluaga-Arbeláez C; Marin-Oyaga V; Rodríguez-González MJ
    Arch Cardiol Mex; 2024 Aug; 94(4):451-458. PubMed ID: 39088727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of right ventricular myocardial stiffness by cardiac elastography in patients with transthyretin amyloidosis.
    Neto ACA; Pereira NM; Romero CE; Cafezeiro CRF; Bueno BVK; Rissato JH; Pereira FL; Chammas MC; Ramires FJA; Mady C; Junior WM; Filho RK; Fernandes F
    Curr Probl Cardiol; 2025 Jan; 50(1):102867. PubMed ID: 39393619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Prognostic Value of Query Amyloid Late Enhancement Score in Light-Chain Cardiac Amyloidosis.
    Wan K; Sun J; Han Y; Liu H; Yang D; Li W; Wang J; Cheng W; Zhang Q; Zeng Z; Chen Y
    Circ J; 2018 Feb; 82(3):739-746. PubMed ID: 29093431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of beta-blocker use by N-terminal pro-brain natriuretic peptide level in acute heart failure patients.
    Kim SJ; Ann SH; Park GM; Kim YG; Park S; Lee SG
    ESC Heart Fail; 2024 Dec; 11(6):3842-3853. PubMed ID: 39015043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing microvascular dysfunction and predicting long-term prognosis in patients with cardiac amyloidosis by CMR quantitative stress perfusion.
    Tang L; Zhao W; Li K; Tian L; Zhou X; Guo H; Zeng M
    J Cardiovasc Magn Reson; 2024 Dec; ():101134. PubMed ID: 39675481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and predictors of sudden death in patients with cardiac amyloidosis.
    de Frutos F; Saturi G; Gonzalez-Lopez E; Sguazzotti M; Dominguez F; Ponziani A; Cabrera-Romero E; Caponetti AG; Lozano S; Massa P; Peiro-Aventin B; Accietto A; Mora-Ayestarán N; Giovannetti A; Castro-Urda V; Gagliardi C; Cobo-Marcos M; Rios-Tamayo R; Biagini E; Gomez-Bueno M; Galiè N; Segovia-Cubero J; Longhi S; Garcia-Pavia P
    Amyloid; 2024 Dec; 31(4):334-338. PubMed ID: 39449197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy.
    Volpentesta E; Kharoubi M; Donadio C; Rebiai K; Fanen P; Funalot B; Gendre T; Audard V; Canoui-Poitrine F; Itti E; Teiger E; Planté-Bordeneuve V; Oghina S; Tixier D; Mallet S; Broussier A; Damy T; Zaroui A
    ESC Heart Fail; 2024 Dec; 11(6):3814-3832. PubMed ID: 39021317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.
    Yu C; Li J; Xu T; Wang W; Yang Y; Zhou C; Wang P; Liu P
    BMC Cancer; 2024 Nov; 24(1):1449. PubMed ID: 39587494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Incremental Value of Native T1 Mapping-Derived Radiomics for The Diagnosis of Amyloid Light-Chain Cardiac Amyloidosis.
    Ma Q; Chen J; Cao L; Wu X; Tan Z; Liu H
    Acad Radiol; 2024 Dec; 31(12):4801-4810. PubMed ID: 39107187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis.
    Kwok CS; Choy CH; Pinney J; Townend JN; Whelan C; Fontana M; Gillmore JD; Steeds RP; Moody WE
    ESC Heart Fail; 2024 Dec; 11(6):3901-3910. PubMed ID: 39041492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.